Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study

The objective of this study was to evaluate the efficacy of the traditional Chinese herbal medicine formula, San-Zhong-Kui-Jian-Tang (SZKJT), on patients with head and neck cancer who underwent concurrent chemoradiotherapy (CCRT). We performed a single-center, open-label, prospective feasibility stu...

Full description

Saved in:
Bibliographic Details
Main Authors: Hsuan-Ting Tang MD, Shi-Chen Ou MD, PhD, Chien-Lun Chu MSc, Ai-Lin Lee MD, Hung-Jen Lin MD, PhD, Ying-Chun Lin MD, Yao-Ching Wang MD, Shih-Neng Yang MD, PhD, Ming-Yu Lien MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2025-03-01
Series:Integrative Cancer Therapies
Online Access:https://doi.org/10.1177/15347354251326946
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850094638257405952
author Hsuan-Ting Tang MD
Shi-Chen Ou MD, PhD
Chien-Lun Chu MSc
Ai-Lin Lee MD
Hung-Jen Lin MD, PhD
Ying-Chun Lin MD
Yao-Ching Wang MD
Shih-Neng Yang MD, PhD
Ming-Yu Lien MD, PhD
author_facet Hsuan-Ting Tang MD
Shi-Chen Ou MD, PhD
Chien-Lun Chu MSc
Ai-Lin Lee MD
Hung-Jen Lin MD, PhD
Ying-Chun Lin MD
Yao-Ching Wang MD
Shih-Neng Yang MD, PhD
Ming-Yu Lien MD, PhD
author_sort Hsuan-Ting Tang MD
collection DOAJ
description The objective of this study was to evaluate the efficacy of the traditional Chinese herbal medicine formula, San-Zhong-Kui-Jian-Tang (SZKJT), on patients with head and neck cancer who underwent concurrent chemoradiotherapy (CCRT). We performed a single-center, open-label, prospective feasibility study from 2018 to 2020. A total of 27 head and neck cancer patients who received CCRT were recruited for the study. SZKJT was given to patients simultaneously with CCRT for 9 weeks. The primary endpoint was the feasibility and completion rate of CCRT, while the secondary endpoint was occurrence of adverse effects. The quality of life (QoL) and traditional Chinese medicine body constitutions were measured by the QLQ-C30 and the Body Constitution Questionnaire (BCQ), respectively. There were 6 dropouts from the study due to complications, while 21 participants completed the trial. Among those 21 participants, 16 completed the CCRT treatment course, yielding a completion rate of 76.2%. The side effects observed during the CCRT and SZKJT trial included dermatitis in 4.8% (Grade 0), 57.1% (Grade 1), and 38.1% (Grade 2), and oral mucositis in 62.0% (Grade 1), 19.0% (Grade 2), and 19.0% (Grade 3) of participants. A comparison of the pre- and post-treatment QLQ-C30 scores revealed that QoL was unaffected ( P  = .506). However, the BCQ results showed significant increases in the Yin-Xu, Yang-Xu, and stasis constitutions ( P  < .001). No serious adverse events were observed due to SZKJT. Preliminary results indicated that additional SZKJT with CCRT was feasible, while noting a high completion CCRT rate (76.2%) among the SZKJT-treated patients. Our study reveals that SZKJT can effectively reduce the severity of dermatitis and oral mucositis associated with CCRT. Larger randomized controlled trials are required to further assess the efficacy and safety of SZKJT. The trial registration number is NCT05590650 on ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05590650
format Article
id doaj-art-b57c58bf291d4fb993cd7a3272d4787c
institution DOAJ
issn 1552-695X
language English
publishDate 2025-03-01
publisher SAGE Publishing
record_format Article
series Integrative Cancer Therapies
spelling doaj-art-b57c58bf291d4fb993cd7a3272d4787c2025-08-20T02:41:37ZengSAGE PublishingIntegrative Cancer Therapies1552-695X2025-03-012410.1177/15347354251326946Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility StudyHsuan-Ting Tang MD0Shi-Chen Ou MD, PhD1Chien-Lun Chu MSc2Ai-Lin Lee MD3Hung-Jen Lin MD, PhD4Ying-Chun Lin MD5Yao-Ching Wang MD6Shih-Neng Yang MD, PhD7Ming-Yu Lien MD, PhD8China Medical University Hospital, Taichung, TaiwanChina Medical University, Taichung, TaiwanChina Medical University Hospital, Taichung, TaiwanChina Medical University Hospital, Taichung, TaiwanChina Medical University, Taichung, TaiwanChina Medical University Hospital, Taichung, TaiwanChina Medical University Hospital, Taichung, TaiwanChina Medical University, Taichung, TaiwanChina Medical University, Taichung, TaiwanThe objective of this study was to evaluate the efficacy of the traditional Chinese herbal medicine formula, San-Zhong-Kui-Jian-Tang (SZKJT), on patients with head and neck cancer who underwent concurrent chemoradiotherapy (CCRT). We performed a single-center, open-label, prospective feasibility study from 2018 to 2020. A total of 27 head and neck cancer patients who received CCRT were recruited for the study. SZKJT was given to patients simultaneously with CCRT for 9 weeks. The primary endpoint was the feasibility and completion rate of CCRT, while the secondary endpoint was occurrence of adverse effects. The quality of life (QoL) and traditional Chinese medicine body constitutions were measured by the QLQ-C30 and the Body Constitution Questionnaire (BCQ), respectively. There were 6 dropouts from the study due to complications, while 21 participants completed the trial. Among those 21 participants, 16 completed the CCRT treatment course, yielding a completion rate of 76.2%. The side effects observed during the CCRT and SZKJT trial included dermatitis in 4.8% (Grade 0), 57.1% (Grade 1), and 38.1% (Grade 2), and oral mucositis in 62.0% (Grade 1), 19.0% (Grade 2), and 19.0% (Grade 3) of participants. A comparison of the pre- and post-treatment QLQ-C30 scores revealed that QoL was unaffected ( P  = .506). However, the BCQ results showed significant increases in the Yin-Xu, Yang-Xu, and stasis constitutions ( P  < .001). No serious adverse events were observed due to SZKJT. Preliminary results indicated that additional SZKJT with CCRT was feasible, while noting a high completion CCRT rate (76.2%) among the SZKJT-treated patients. Our study reveals that SZKJT can effectively reduce the severity of dermatitis and oral mucositis associated with CCRT. Larger randomized controlled trials are required to further assess the efficacy and safety of SZKJT. The trial registration number is NCT05590650 on ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05590650https://doi.org/10.1177/15347354251326946
spellingShingle Hsuan-Ting Tang MD
Shi-Chen Ou MD, PhD
Chien-Lun Chu MSc
Ai-Lin Lee MD
Hung-Jen Lin MD, PhD
Ying-Chun Lin MD
Yao-Ching Wang MD
Shih-Neng Yang MD, PhD
Ming-Yu Lien MD, PhD
Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study
Integrative Cancer Therapies
title Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study
title_full Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study
title_fullStr Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study
title_full_unstemmed Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study
title_short Chinese Herbal Medicine for Concurrent Chemoradiation-Induced Adverse Events in Head and Neck Cancer Patients: A Prospective Feasibility Study
title_sort chinese herbal medicine for concurrent chemoradiation induced adverse events in head and neck cancer patients a prospective feasibility study
url https://doi.org/10.1177/15347354251326946
work_keys_str_mv AT hsuantingtangmd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT shichenoumdphd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT chienlunchumsc chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT ailinleemd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT hungjenlinmdphd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT yingchunlinmd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT yaochingwangmd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT shihnengyangmdphd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy
AT mingyulienmdphd chineseherbalmedicineforconcurrentchemoradiationinducedadverseeventsinheadandneckcancerpatientsaprospectivefeasibilitystudy